UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report: April 20, 2005
(Date of earliest event reported)
Specialty Laboratories, Inc.
(Exact name of registrant as specified in its charter)
|
California |
|
001-16217 |
|
95-2961036 |
|
(State or Other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
|
27027 Tourney Road, Valencia, California |
|
91355 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
(661) 799-6543
(Registrant’s telephone number, including area code)
Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition
On April 20, 2005, the Company announced financial results for the first quarter ended March 31, 2005. A copy of the press release issued by the Company on April 20, 2005 concerning the foregoing matter is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure
On April 20, 2005, the Company issued a press release announcing financial results for the first quarter ended March 31, 2005. The press release is attached as Exhibit 99.1 to this report.
Limitation on Incorporation by Reference: In accordance with General Instruction B.2 of Form 8-K, the information in this report is furnished under Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liability of that section.
Item 9.01 Financial Statements and Exhibits
(c) Exhibit. The following document is filed as an exhibit to this report.
99.1 Press Release dated April 20, 2005.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: April 20, 2005 |
|
|
|
|
|
SPECIALTY LABORATORIES, INC. |
||
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Kevin R. Sayer |
|
|
|
|
Kevin R. Sayer |
|
|
|
|
Chief Financial Officer |
|
3
EXHIBIT INDEX
The following document is filed as an exhibit to this report:
Exhibits
99.1 Press Release dated April 20, 2005
4